Showing 27,281 - 27,300 results of 27,432 for search '(( 50 ((teer decrease) OR (mean decrease)) ) OR ( 50 ((c decrease) OR (a decrease)) ))', query time: 1.24s Refine Results
  1. 27281

    Table 4_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

    Published 2025
    “…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. From an age effect perspective, globally, over 50% of COPD prevalence is concentrated among individuals aged 65 years and older, particularly in middle, low-middle, and high-middle SDI regions. …”
  2. 27282

    Supplementary file 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period... by Wubing Cao (20821589)

    Published 2025
    “…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. From an age effect perspective, globally, over 50% of COPD prevalence is concentrated among individuals aged 65 years and older, particularly in middle, low-middle, and high-middle SDI regions. …”
  3. 27283

    Table 2_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

    Published 2025
    “…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. From an age effect perspective, globally, over 50% of COPD prevalence is concentrated among individuals aged 65 years and older, particularly in middle, low-middle, and high-middle SDI regions. …”
  4. 27284

    Table 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

    Published 2025
    “…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. From an age effect perspective, globally, over 50% of COPD prevalence is concentrated among individuals aged 65 years and older, particularly in middle, low-middle, and high-middle SDI regions. …”
  5. 27285

    Table 3_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

    Published 2025
    “…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. From an age effect perspective, globally, over 50% of COPD prevalence is concentrated among individuals aged 65 years and older, particularly in middle, low-middle, and high-middle SDI regions. …”
  6. 27286

    Table 7_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

    Published 2025
    “…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. From an age effect perspective, globally, over 50% of COPD prevalence is concentrated among individuals aged 65 years and older, particularly in middle, low-middle, and high-middle SDI regions. …”
  7. 27287

    Supplementary file 2_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period... by Wubing Cao (20821589)

    Published 2025
    “…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. From an age effect perspective, globally, over 50% of COPD prevalence is concentrated among individuals aged 65 years and older, particularly in middle, low-middle, and high-middle SDI regions. …”
  8. 27288

    DataSheet1_Identification of immune-related biomarkers for intracerebral hemorrhage diagnosis based on RNA sequencing and machine learning.docx by Congxia Bai (11728634)

    Published 2024
    “…Background<p>Intracerebral hemorrhage (ICH) is a severe stroke subtype with high morbidity, disability, and mortality rates. …”
  9. 27289

    Table_2_“Longitudinal Fecal Microbiome Study of Total Body Irradiated Mice Treated With Radiation Mitigators Identifies Bacterial Associations With Survival”.xlsx by Kelvin Li (158276)

    Published 2021
    “…Survival improved relative to control (30.0%) for G-CSF (80%, p-value = 0.025), G-CSF/JP4-039 (70%, p-value = 0.084), but not for JP4-039 (50.0%). In the second experiment, mice were administered mitigation drugs “inhibiting programmed cell death” pathways: JP4-039 (anti-apoptosis), necrostatin-1 (anti-necroptosis), and baicalein (anti-ferroptosis), in eight combinations. …”
  10. 27290

    Table_3_“Longitudinal Fecal Microbiome Study of Total Body Irradiated Mice Treated With Radiation Mitigators Identifies Bacterial Associations With Survival”.xlsx by Kelvin Li (158276)

    Published 2021
    “…Survival improved relative to control (30.0%) for G-CSF (80%, p-value = 0.025), G-CSF/JP4-039 (70%, p-value = 0.084), but not for JP4-039 (50.0%). In the second experiment, mice were administered mitigation drugs “inhibiting programmed cell death” pathways: JP4-039 (anti-apoptosis), necrostatin-1 (anti-necroptosis), and baicalein (anti-ferroptosis), in eight combinations. …”
  11. 27291

    Table_1_“Longitudinal Fecal Microbiome Study of Total Body Irradiated Mice Treated With Radiation Mitigators Identifies Bacterial Associations With Survival”.docx by Kelvin Li (158276)

    Published 2021
    “…Survival improved relative to control (30.0%) for G-CSF (80%, p-value = 0.025), G-CSF/JP4-039 (70%, p-value = 0.084), but not for JP4-039 (50.0%). In the second experiment, mice were administered mitigation drugs “inhibiting programmed cell death” pathways: JP4-039 (anti-apoptosis), necrostatin-1 (anti-necroptosis), and baicalein (anti-ferroptosis), in eight combinations. …”
  12. 27292

    Table1_Identification of immune-related biomarkers for intracerebral hemorrhage diagnosis based on RNA sequencing and machine learning.xlsx by Congxia Bai (11728634)

    Published 2024
    “…Background<p>Intracerebral hemorrhage (ICH) is a severe stroke subtype with high morbidity, disability, and mortality rates. …”
  13. 27293

    Table_1_Dietary Patterns Are Associated With Multi-Dimensional Cognitive Functions Among Adults Aged 55 and Older in China.DOCX by Qiumin Huang (10902231)

    Published 2022
    “…Background<p>The intake of certain food and nutrients may play a crucial role in cognitive health. However, research on the relationship between dietary patterns and cognitive function is limited. …”
  14. 27294

    Table_1_Effect of short-term mindfulness-based stress reduction on sleep quality in male patients with alcohol use disorder.DOCX by Yongmei Wang (105230)

    Published 2023
    “…</p>Objective<p>The aim of the present study was to evaluate the effect of short-term MBSR on sleep quality in male patients with AUD after withdrawal.</p>Methods<p>A total of 91 male patients with AUD after 2 weeks of routine withdrawal therapy were randomly divided into two groups using a coin toss: the treatment group (n = 50) and the control group (n = 41). …”
  15. 27295

    DataSheet1_Phytochemical characterization of Typha domingensis and the assessment of therapeutic potential using in vitro and in vivo biological activities and in silico studies.pd... by Rizwana Dilshad (17354662)

    Published 2023
    “…TDME demonstrated significant (p < 0.05) potential in analgesic activity by hot plate and tail immersion tests and anti-inflammatory activity by the carrageenan-induced hind paw edema model. Pain latency decreased significantly, and the anti-inflammatory effect increased in a dose-dependent way. …”
  16. 27296

    Supplementary Material for: Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation by Yang S. (3704074)

    Published 2021
    “…<b><i>Methods:</i></b> This is a post hoc analysis of a multicenter, phase-3 trial (NCT01973387). …”
  17. 27297

    Table_1_BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.pdf by Maria Stella Pennisi (6371525)

    Published 2019
    “…Thus, we retrospectively examined BCR-ABL1 evolution in 305 chronic-phase CML patients receiving imatinib mesylate (IM) as a first line treatment. Patients were subdivided in two groups: those with a confirmed rise in BCR-ABL1 transcripts without MR<sup>3.0</sup> loss and those failing IM. …”
  18. 27298

    Data_Sheet_1_Increased fruit intake is associated with reduced risk of depression: evidence from cross-sectional and Mendelian randomization analyses.docx by Zhaoqi Yan (11322876)

    Published 2023
    “…Fruit intake was also associated with a decreased risk of neuroticism traits related to depression, including feeling lonely (OR = 0.82, 95% CI = 0.74–0.90; p = 2.91E-05), feeling miserable (OR = 0.79, 95% CI = 0.72–0.87; p = 2.35E-06), feeling fed-up (OR = 0.75, 95% CI = 0.68–0.83; p = 2.78E-08), irritable mood (OR = 0.89, 95% CI = 0.79–0.99; p = 0.03), and neuroticism (OR = 0.85, 95% CI = 0.76–0.96; p = 9.94E-03). …”
  19. 27299

    Data_Sheet_1_BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.PDF by Maria Stella Pennisi (6371525)

    Published 2019
    “…Thus, we retrospectively examined BCR-ABL1 evolution in 305 chronic-phase CML patients receiving imatinib mesylate (IM) as a first line treatment. Patients were subdivided in two groups: those with a confirmed rise in BCR-ABL1 transcripts without MR<sup>3.0</sup> loss and those failing IM. …”
  20. 27300

    Plasma MicroRNAs as Potential Noninvasive Biomarkers for In-Stent Restenosis by Meijiao He (666387)

    Published 2014
    “…</p><p>Methods</p><p>This retrospective, observational single-centre study was conducted at the cardiovascular department of a tertiary hospital centre in the north of China. …”